SCHEMBL23612428

SCHEMBL23612428

CC(C)c1ccc2c(c1)OC(F)(F)C(=O)N2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.37
MAPT P10636 3/20 0.37
MEN1 O00255 2/20 0.37
XBP1 P17861 2/20 0.37
HTT P42858 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37
MDM2 Q00987 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HPGD P15428 1/20 0.36
GFER P55789 1/20 0.36
HSD17B10 Q99714 1/20 0.36
BRD4 O60885 8/20 0.34
PAX8 Q06710 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RNASEH1 O60930 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12709607 0.88 MEN1 (0.36) KMT2AMAPTMEN1XBP1HTT
SCHEMBL13340910 0.83 BRD4 (0.48) KMT2AMAPTMEN1XBP1HTT
SCHEMBL20436332 0.79 HTT (0.49) KMT2AMAPTXBP1HTTSMN1; SMN2
SCHEMBL17027037 0.78 HPGD (0.37) KMT2AMAPTMEN1XBP1HTT
SCHEMBL900430 0.77 KMT2A (0.45) KMT2AMAPTXBP1HTTBRD4
SCHEMBL32683704 0.76 LMNA (0.43) KMT2AMAPTMEN1ALDH1A1LMNA
SCHEMBL31694220 0.76 LMNA (0.43) KMT2AMAPTMEN1ALDH1A1LMNA
SCHEMBL23612470 0.76 KMT2A (0.51) KMT2AMAPTMEN1XBP1HTT
SCHEMBL32683362 0.73 ALDH1A1 (0.39) KMT2AMAPTMEN1XBP1HTT
SCHEMBL13340900 0.73 BRD4 (0.35) BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11052092-B2 N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases GENFIT (FR) 2021-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11052092-B2 N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases RORA, RORC, RORB KMT2A 635/4885MAPT 3199/4885MEN1 4303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.